EVALUATION OF SURGICAL FACTORS AFFECTING VITREOUS HEMORRHAGE FOLLOWING PORT DELIVERY SYSTEM WITH RANIBIZUMAB IMPLANT INSERTION IN A MINIPIG MODEL

Retina. 2020 Aug;40(8):1520-1528. doi: 10.1097/IAE.0000000000002614.

Abstract

Purpose: To develop an animal model of vitreous hemorrhage (VH) to explore the impact of surgical parameters on VH associated with insertion of the Port Delivery System with ranibizumab (PDS) implant.

Methods: Ninety eyes from 45 treatment-naive male Yucatan minipigs received PDS implant insertion or a sham procedure. The effect of prophylactic pars plana hemostasis, scleral incision length, scleral cauterization, surgical blade type/size, and viscoelastic usage on postsurgical VH was investigated.

Results: Postsurgical VH was detected in 60.0% (54/90) of implanted eyes. A systematic effect on VH was only detected for pars plana hemostasis before the pars plana incision. The percentage of eyes with VH was 96.6% (28/29) among eyes that did not receive prophylactic pars plana hemostasis and 42.4% (24/58) among eyes that did. There was no VH in eyes that received laser ablation of the pars plana using overlapping 1,000-ms spots; pars plana cautery or diathermy was less effective. The majority of all VH cases (83.3% [45/54]) were of mild to moderate severity (involving ≤25% of the fundus).

Conclusion: In this minipig surgical model of VH, scleral dissection followed by pars plana laser ablation before pars plana incision most effectively mitigated VH secondary to PDS implant insertion.

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Animals
  • Disease Models, Animal*
  • Drug Delivery Systems*
  • Drug Implants
  • Follow-Up Studies
  • Homeostasis
  • Intraocular Pressure / physiology
  • Male
  • Ranibizumab / administration & dosage*
  • Sclera / surgery*
  • Swine
  • Swine, Miniature
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology
  • Vitreous Body / drug effects*
  • Vitreous Hemorrhage / diagnosis
  • Vitreous Hemorrhage / etiology*
  • Vitreous Hemorrhage / prevention & control

Substances

  • Angiogenesis Inhibitors
  • Drug Implants
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Ranibizumab